Immune checkpoint inhibitors (ICIs) have dramatically updated tumor therapeutic regimens, including therapies targeting programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4). Here, PDCD1 is linked to neoplasm.